Company
Faron Pharmaceuticals Limited
LON:FARN
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
418 stories · page 2 of 5
Faron Pharma reports encouraging start to leukaemia trial
No dose-limiting toxicities or safety concerns were observed among five patients to have received the initial dose
Faron Pharma gets reiterated 'buy' rating from Peel Hunt following Bexmarilimab therapy news
The City broker's analysts said: "We already knew that data was promising across all the indication areas (eg the recent top-line data on Bexmarilimab dose variation), and this news today is an incremental positive"
Faron Pharma's cancer treatment has the capacity to ignite immunity in people with late-stage skin cancer
The company's MATINS study is assessing how its promising cancer drug, bexmarilimab, performs in 10 treatment-resistant tumour types. The data below is from the melanoma group
Faron Pharma: Broker reiterates 'buy' and price target after accelerated fundraiser
Peel Hunt, the company's corporate broker, reckons the stock is worth 524p
Faron Pharma says cancer programme to be fast tracked after successful €8mln fundraiser
Bexmarilimab has shown promise in an early-stage clinical trial
Faron Pharmaceuticals hails potential of cancer immunotherapy as it updates early-phase trial data
The survival rate of those taking bexmarilimab was almost 15 months - significantly higher than those not receiving the treatment
Faron Pharma says study points to the promise of its drug in emergency and trauma patients
Data from the study will be presented at the Military Health System Research Symposium
Faron Pharma to accelerate clinical development of cancer treatment Bexmarilimab
A study showed 100% of checkpoint refractory skin cancer and bile duct cancer patients treated with Bexmarilimab survived for a year
Faron Pharma raises €5mln; brings in leading charity as an investor
The fundraiser won the backing of the Leukemia & Lymphoma Society Therapy Acceleration Program
Faron Pharma encouraged by survival rates in latest MATINS trial data
Faron said the strongest survival benefit was seen in refractory skin cancer and bile duct cancer.
Faron Pharmaceuticals doses first patient in bexmarilimab combination study
The trial marks the first time the company's bexmarilimab immunotherapy asset is being assessed as part of a clinical study in hematologic malignancies
Faron Pharma to showcase the potential of cancer drug at ASCO conference
Drawing on work carried out via its MATINS trial, the American Society of Clinical Oncology will be given a number of data insights
Faron Pharma receives regulators' green light to begin phase I/II trial of promising cancer drug candidate
Investigational new drug applications have been approved in the US and Finland
Faron Pharmaceuticals Oy: Research underlines the potential of lead cancer asset
The article in the journal Molecular Cancer Therapeutics looked at early-stage data, before assessing the potential of bexmarilimab
Faron Pharma to present data from MATINS cancer trial to European melanoma experts
The melanoma cohort is one of the ten advanced treatment-resistant solid tumour types included in Part II of the trial
Faron Pharmaceuticals halts COVID-19 trial as hospital cases drop
The decision was based on a recommendation from the trial’s Independent Data Monitoring Committee (IDMC)
Faron Pharmaceutical heading into 'most important year in its history' says CEO
"Bexmarilimab has the potential to bring the promise of immunotherapy to many more patients"
Faron Pharma identifies possible reason for interferon-beta and steroid clash
The polymorphism, SNP rs9984273, is relatively common, said Faron
Faron Pharmaceuticals will present findings at American Association for Cancer Research annual meeting
The ongoing open-label Phase I/II MATINS clinical trial is investigating the safety and efficacy of bexmarilimab, which is being investigated as a potential monotherapy in patients with solid tumours who have exhausted all other treatment o
Faron Pharmaceuticals agrees funding deal worth up to €30mln
"This financing agreement will notably help us continue to accelerate our ambitious bexmarilimab development programme, which has the potential to bring the promise of immunotherapy to a much broader patient population compared to the relat
Faron Phamraceuticals encouraged by survival data from MATINS cancer trial
Updated results showed 70% of patients receiving treatment had survived nine months
Faron Pharmaceuticals to host virtual R&D day
Faron's new chief medical officer, Dr Marie-Louise Fjällskog, will provide an update on bexmarilimab, the company's wholly-owned novel precision cancer immunotherapy
Faron Pharmaceuticals says Traumakine study shows induction of CD73 molecule prevents death after emergency open aortic surgery
The biopharmaceutical company said its INFORAAA study revealed that up-regulation of CD73 was associated with 100% survival
Faron announces new chief operating officer to catapult cancer immunotherapy development
The new role will include the oversight of academic and industry partnerships, resource prioritisation and allocation, chemistry, manufacturing and controls, supply chain, and driving performance measures
Faron Pharmaceuticals hires new chief medical officer
The newcomer will be tasked with accelerating the company’s clinical development programmes
Faron Pharmaceuticals says biomarker study yields 'exciting' findings
The top-line analysis of the latest patient feedback reveals the bexarilimab ignites a response from those that have not traditionally benefited from current immunotherapy treatments
Proactive news headlines: Faron Pharmaceuticals, Supermarket Income, Nuformix...
A glance at some of the day's highlights from the Proactive Investors newswire
Faron Pharma awarded €3.8mln following Rentschler arbitration
The claim related to a manufacturing agreement for Faron's drug Traumakine
Faron Pharma raises €10.5mln to support two key drug candidates
The share placing was supported by the European Innovation Council
Faron Pharma says study provides 'compelling' evidence cancer drug increases survival in patients with late-stage tumours
"The efficacy and survival data are particularly compelling when you consider the late-stage, treatment-refractory disease patient population and inclusion of nonimmunogenic cold tumours in the trial," said Petri Bono, principal investigato
Faron Pharma set to see the clinical momentum continue after a strong first half
Chief executive Dr Markku Jalkanen said he was "extremely proud" of the progress made over the first half
Faron Pharma: City broker provides its commentary on Covid trial
“We agree with that company, that IFNb (Faron’s formulation and treatment paradigm) is a promising asset in the treatment of coronavirus,” Peel Hunt said in a note to clients
Faron Pharmaceuticals researchers dose first patient in pivotal COVID-19 trial
The HIBISCUS study will be conducted across 10-15 sites in the US and will enrol 140 patients
Faron Pharmaceuticals’ bexmarilimab secures key US patent
The new patent covers the composition of matter of the cancer immunotherapy drug candidate and is expected to expire in 2037
Faron Pharmaceuticals flags up latest research assessing the potential of bexmarilimab in advanced cancer patients
The data, compiled by Dr Maija Hollmén and colleagues at the University of Turku, was published in the journal, Clinical Cancer Research
Faron Pharmaceuticals flags up latest research assessing the potential of bexmarilimab in advanced cancer patients
The data, compiled by Dr Maija Hollmén and colleagues at the University of Turku, was published in the journal, Clinical Cancer Research
Faron Pharmaceuticals reveals promising data from a clinical study of Bexmarilimab
"Bexmarilimab's ability to increase survival in patients who have exhausted all treatment options is significant," said Markku Jalkanen, Faron’s chief executive officer
Faron Pharmaceuticals in US sub-licence deal
It said the agreement clarifies its intellectual property position in the US
Faron Pharma making progress in finding potential partners for Clevegen and Traumakine
While discussions with potential partners proceed, the company has received substantial funding support from the market, putting it in a strong position to continue the progress of its pipeline
Faron Pharma says trial on precision cancer drug shows significant efficacy signals
The study's data monitoring committee has suggested investigating more frequent dosing schedules in patients showing early clinical benefit
Faron Pharma raises €15mln to 'expand and accelerate' work in the clinic
The European Investment Council Fund was the largest new investor
Faron Pharmaceuticals enjoys momentum as COVID-19 drug candidate gets green light for late-stage trials
Traumakine has also attracted the interest of the US Department of Defense, which was revealed to be a surprise backer
Faron Pharmaceuticals says US regulator gives phase II/III coronavirus trial the green light
Traumakine, an intravenous interferon beta-1a drug, will be given to people who have been hospitalised but who do not yet need ventilation
Archive
Proactive news headlines: Faron Pharmaceuticals, ANGLE, CMC Markets, Bango ...
A glance at some of the day's highlights from the Proactive Investors newswire
Faron Pharmaceuticals says research suggests immune-stimulating effects of its drug may be broader than first thought
Faron has been working with Kaiku Health, a data science company that uses an artificial intelligence platform to analyse patient results following treatment with cancer immunotherapies
Faron Pharmaceuticals says US Department of Defense gets behind coronavirus study with US$6.1mln of funding
Faron will be working directly with the 59th Medical Wing of the US Air Force
Faron Pharmaceuticals: Scientists to showcase progress and scientific thinking in two presentations at leading cancer forum
Researchers have presentation slots at the European Society of Medical Oncology Immuno-Oncology Virtual Congress
Faron Pharma reports solid progress with phase I/II cancer trial; plans further studies
The company said it was seeing “exciting clinical activity across multiple cancer types” from bexmarilimab, formerly Clevegen
Faron Pharma says disappointed but not surprised by WHO coronavirus trial data
“They do support our long-held view that IFN beta-1a is likely to be ineffective when given subcutaneously."
Faron Pharma expects data from COVID-19 treatment trial in final quarter of 2020
Traumakine, an intravenously administered interferon beta -1a treatment, is part of the World Health Organisation’s global SOLIDARITY trial
Faron Pharma says scientist to discuss “promising” anti-tumour activity of phase I/II drug at leading cancer forum
Dr Petri Bono will take part in an on-demand segment at the European Society of Medical Oncology Virtual Congress
Faron Pharmaceuticals rises after Traumakine update
Faron is supporting global research efforts against coronavirus (COVID-19) and looks forward to receiving further data from clinical trials to support the potential use of Traumakine (IV IFN beta-1a)
Archive
Proactive news headlines: Clipper Logistics, AfriTin Mining, Faron Pharma, Union Jack Oil, Eckoh ...
A glance at some of the day's highlights from the Proactive Investors newswire
Faron Pharma updates on progress of Clevegen and Traumakine ahead of R&D day
The biopharma firm said Trumakine will now be subject to a third trial to investigate whether the company’s IV IFN beta-1a can treat coronavirus
Faron Pharma plans to initiate new state of the art process for manufacture of interferon (IFN) beta-1a
To support this, Faron said, it has received a €2,100,000 low interest rate loan from Business Finland, the governmental innovation financing agency of Finland.
Faron Pharma receives €2.5mln to accelerate cancer clinical trial
The award has come from the European Innovation Council Accelerator pilot scheme, which exists to support small companies and scientists working on breakthrough products
Faron Pharma shares trial data at ASCO; updates on cancer trial recruitment
The poster presentation will show Faron’s precision cancer immunotherapy Clevegen was well-tolerated without ‘dose-limiting toxicities'
Faron Pharmaceuticals chief hails as crucial new data that help explain unexpected phase III result
Dr Markku Jalkanen applauded the "scientific detective work" carried out during the analysis of glucocorticoids
Faron Pharmaceuticals jumps as it secures grant from Business Finland
Faron said the €800,000 grant will enable characterisation of immunological responses in its MATINS trial, which is currently investigating the tolerability, safety and efficacy of its Clevegen precision cancer immunotherapy
Archive
Small Cap Wrap - FARON Pharma; Kingswood Holdings;Gaming Realms;
FARON Pharma 370p £173m (AIM:FARN) A global contract development and manufacturing organisation AGC Biologics has been selected to be the commercial scale manufacturer of Clevegen, Faron's wholly-owned novel precision cancer immunotherapy t
Faron Pharma selects manufacturing partner for cancer immunotherapy drug candidate
AGC Biologics will help support the expansion of trials of Clevegen
Faron Pharmaceuticals confident on the potential of both its coronavirus and cancer candidates
The phase I/II MATINS study for Clevegen has recently been expanded.
Faron Pharma donates drug for landmark World Health Organisation coronavirus trial
The group is supplying experimental treatment Traumakine to 2,000 patients
Archive
Small Cap Wrap - NQ Minerals; Faron Pharma and more...
Faron Pharma 355p £154m (AIM:FARN.) Result of placing and issue price. Subject to all conditions being met, the aggregate gross proceeds of the Placing will be up to EUR14 million (£12.18 million) before expenses at EUR4. A discount of 7.6
Faron Pharma raises quick-fire £12.8mln to fund development of two key drug candidates
Faron chief executive, Dr Markku Jalkanen, said the injection of cash would help the company build on the progress of the last year as well as “bring significant value for shareholders during the next 8-12 months
Faron Pharmaceuticals drug accepted to global pneumonia programme
The study will include patients suffering from coronavirus (COVID-19)
Faron Pharma receives green light to broaden MATINS cancer study
An assessment of 30 patients looking into the drug’s tolerability, safety and efficacy found that all bar those receiving the lowest levels of the treatment were subject to dose-related immune activation
Archive
Small Cap Wrap - DRI Healthcare, Faron Pharma, Tracsis and more...
Dish of the day No Joiners Today Off the menu No Leavers Today What’s cooking in the IPO kitchen?
Faron Pharmaceuticals says Clevegen partnership discussions continue
An update was provided in Faron’s 2019 results statement
Proactive news snapshot: Open Orphan, Faron Pharmaceuticals, Greatland Gold...
A look at some of the top stories from the Proactive newswire on Monday
Faron Pharma gets US regulatory green light for late-stage trial
The study set-up reflects feedback from the Food & Drug Administration
Faron Pharmaceuticals study sees second partial response to cancer drug
In Part I of the MATINS trial it was discovered the lung metastasis of a melanoma patient shrank by 44% after receiving the Faron drug